Article
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Journal of the National Cancer Institute - 8 Dec 2014
Goetz Matthew P, Sun James X, Suman Vera J, Silva Grace O, Perou Charles M, Nakamura Yusuke, Cox Nancy J, Stephens Philip J, Miller Vincent A, Ross Jeffrey S, Chen David, Safgren Stephanie L, Kuffel Mary J, Ames Matthew M, Kalari Krishna R, Gomez Henry L, Gonzalez-Angulo Ana M, Burgues Octavio, Brauch Hiltrud B, Ingle James N, Ratain Mark J, Yelensky Roman
Abstract excerpt
BACKGROUND: Controversy exists regarding the impact of CYP2D6 genotype on tamoxifen responsiveness. We examined loss of heterozygosity (LOH) at the CYP2D6 locus and determined its impact on genotyping error when tumor tissue is used as a DNA source. METHODS: Genomic tumor data from the adjuvant and metastatic settings (The Cancer Genome Atlas [TCGA] and Foundation Medicine [FM]) were analyzed to characterize the...
Topics
- Adult
- Aged
- Antineoplastic Agents, Hormonal
- Biomarkers, Tumor
- Breast Neoplasms
- Cytochrome P-450 CYP2D6
- DNA, Neoplasm
- Disease-Free Survival